Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8021
Reference
Name
National Patient Safety Alert – Potential for inappropriate dosing of insulin when switching insulin Degludec (Tresiba®) products
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
HEALTH BOARDS
NATIONAL PATIENT SAFETY ALERT
DRUG SHORTAGE
TRESIBA INJECTION PENS
DRUG ERRORS
Description
A Medicine Supply Notification issued on 24 May 2023, detailed a shortage of Tresiba® (insulin degludec) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens. Advice on how to manage this supply issue can be found on the Medicine Supply Tool. The Medication Safety Officer (MSO) network has highlighted that in response to this shortage, some patients may have been switched to Tresiba® (insulin degludec) FlexTouch® 200units/ml solution for injection 3ml pre-filled pens. Tresiba® FlexTouch® pen delivery devices dial up in unit increments rather than volume. However, a small number of patients have been incorrectly advised to administer half the number of units. MSOs have highlighted five reports of patients being incorrectly advised to reduce the number of units of insulin to be administered. These reports suggest that errors have occurred at the prescribing, dispensing and administration stages of the medicine journey. One case described a patient requiring treatment in hospital for diabetic ketoacidosis because of a reduced insulin dose.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2023-12-08 00:00:00
Click to go back to homepage